Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition

SHP2 (PTPN11) acts upstream of SOS1/2 to enable RAS activation. Allosteric SHP2 inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK- or cycling RAS mutant-driven cancers, and overcome “adaptive resistance.” To identify SHP2i resistance mechanisms, we performed genome...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wei, Geer, Mitchell J., Guo, Xinyi, Dolgalev, Igor, Sanjana, Neville E., Neel, Benjamin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998968/
https://www.ncbi.nlm.nih.gov/pubmed/36820830
http://dx.doi.org/10.1084/jem.20221563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998968/
https://www.ncbi.nlm.nih.gov/pubmed/36820830
http://dx.doi.org/10.1084/jem.20221563

Ejemplares similares